Identification and treatment of aggressive thyroid cancers part 2: Risk assessment and treatment

ONCOLOGY

Volumn 20, Issue 4, 2006, Pages 397-404

  Sturgeon, Cord ^a,b   Angelos, Peter ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CETUXIMAB; CIGLITAZONE; CISPLATIN; DOXORUBICIN; GANCICLOVIR; INTERLEUKIN 12; PIOGLITAZONE; RADIOACTIVE IODINE; RECOMBINANT INTERLEUKIN 2; ROSIGLITAZONE; THYROGLOBULIN; TRASTUZUMAB; TROGLITAZONE; VINDESINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER THERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ASSESSMENT; DRUG EFFECT; EXTERNAL BEAM RADIOTHERAPY; GENE THERAPY; HUMAN; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; THYROID CANCER; THYROIDECTOMY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY; DISEASE COURSE; PATHOLOGY; RISK ASSESSMENT; SURVIVAL; THYROID TUMOR; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CISPLATIN; DISEASE PROGRESSION; GENE THERAPY; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; THIAZOLIDINEDIONES; THYROID NEOPLASMS;

EID: 33750108302     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Greene FL, Page DL, Fleming ID, et al (eds): AJCC Cancer Staging Manual, 6th ed, p 435. Berlin, Springer, 2002.
2. Hay ID, Grant CS, Taylor WF, et al: Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: A retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 102:1088-1095, 1987.
3. Cady B, Rossi R: An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104:947-953, 1988.
4. Hay ID, Bergstralh EJ, Goellner JR, et al: Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050-1057; discussion 1057-1058, 1993.
5. Clark OH: Papillary thyroid carcinoma: Rationale for total thyroidectomy, in Clark OH, Duh QY, Kebebew E (eds): Textbook of Endocrine Surgery, 2nd ed, pp 110-114. Philadelphia, Elsevier Saunders, 2005.
6. McIver B, Hay I: Postoperative management of differentiated thyroid carcinoma, in Doherty G, Skogseid B (eds): Surgical Endocrinology, pp 87-108. Philadelphia, Lippincott Williams & Wilkins, 2001.
7. Asa SL, Bedard YC: Fine-needle aspiration cytology and histopathology, in Clark OH, Noguchi S (eds): Thyroid Cancer: Diagnosis and Treatment, pp 105-126. St. Louis, Quality Medical Publishing, 2000.
8. Bocca E, Pignataro O, Oldini C, et al: Functional neck dissection: An evaluation and review of 843 cases. Laryngoscope 94:942-945, 1984.
9. Attie JN, Khafif RA, Steckler RM: Elective neck dissection in papillary carcinoma of the thyroid. Am J Surg 122:464-471, 1971.
10. Marchetta FC, Sako K, Matsuura H: Modified neck dissection for carcinoma of the thyroid gland. Am J Surg 120:452-455, 1970.
11. Mazzaferri EL, Robbins RJ, Spencer CA, et al: A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88:1433-1441, 2003.
12. Kresnik E, Gallowitsch HJ, Mikosch P, et al: Fluorine-18- fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. Surgery 133:294-299, 2003.
13. Adler LP, Bloom AD: Positron emission tomography of thyroid masses. Thyroid 3:195-200, 1993.
14. Bloom AD, Adler LP, Shuck JM: Determination of malignancy of thyroid nodules with positron emission tomography. Surgery 114:728-734; discussion 734-725, 1993.
15. Kang KW, Kim SK, Kang HS, et al: Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 88:4100-4104, 2003.
16. Van den Bruel A, Maes A, De Potter T, et al: Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma. J Clin Endocrinol Metab 87:1517-1520, 2002.
17. Davis PW, Perrier ND, Adler L, et al: Incidental thyroid carcinoma identified by positron emission tomography scanning obtained for metastatic evaluation. Am Surg 67:582-584, 2001.
18. Cohen MS, Arslan N, Dehdashti F, et al: Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 130:941-946, 2001.
19. Feine U, Lietzenmayer R, Hanke JP, et al: Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 37:1468-1472, 1996.
20. Wang W, Macapinlac H, Larson SM, et al: [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84:2291-2302, 1999.
21. Grunwald F, Kalicke T, Feine U, et al: Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: Results of a multicentre study. Eur J Nucl Med 26:1547-1552, 1999.
22. Wang W, Larson SM, Fazzari M, et al: Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 85:1107-1113, 2000.
23. Grunwald F, Menzel C, Bender H, et al: Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 7:327-335, 1997.
24. Hooft L, Hoekstra OS, Deville W, et al: Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. J Clin Endocrinol Metab 86:3779-3786, 2001.
25. Robbins R, Drucker W, Hann L, et al: Advances in the detection of residual thyroid carcinoma. Adv Intern Med 46:277-294, 2001.
26. Mazzaferri EL, Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428, 1994.
27. Mazzaferri EL: Management of a solitary thyroid nodule. N Engl J Med 328:553-559, 1993.
28. Ruegemer JJ, Hay ID, Bergstralh EJ, et al: Distant metastases in differentiated thyroid carcinoma: A multivariate analysis of prognostic variables. J Clin Endocrinol Metab 67:501-508, 1988.
29. Samaan NA, Schultz PN, Haynie TP, et al: Pulmonary metastasis of differentiated thyroid carcinoma: Treatment results in 101 patients. J Clin Endocrinol Metab 60:376-380, 1985.
30. Shimaoka K, Schoenfeld DA, DeWys WD, et al: A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155-2160, 1985.
31. Scherubl H, Raue F, Ziegler R: Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol 116:21-23, 1990.
32. Fagin JA: How thyroid tumors start and why it matters: Kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 183:249-256, 2004.
33. Nikiforova MN, Stringer JR, Blough R, et al: Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science 290:138-141, 2000.
34. Santoro M, Thomas GA, Vecchio G, et al: Gene rearrangement and Chernobyl related thyroid cancers. Br J Cancer 82:315-322, 2000.
35. Wells SA, Jr, Chi DD, Toshima K, et al: Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 220:237-247; discussion 247-250, 1994.
36. Mulligan LM, Kwok JB, Healey CS, et al: Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460, 1993.
37. Donis-Keller H, Dou S, Chi D, et al: Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851-856, 1993.
38. Kroll TG, Sarraf P, Pecciarini L, et al: PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 289:1357-1360, 2000.
39. Marques AR, Espadinha C, Catarino AL, et al: Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87:3947-3952, 2002.
40. Nikiforova MN, Biddinger PW, Caudill CM, et al: PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 26:1016-1023, 2002.
41. Cohen Y, Xing M, Mambo E, et al: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625-627, 2003.
42. Fukushima T, Suzuki S, Mashiko M, et al: BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22:6455-6457, 2003.
43. Trovisco V, Vieira de Castro I, Soares P, et al: BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 202:247-251, 2004.
44. Nikiforova MN, Kimura ET, Gandhi M, et al: BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404, 2003.
45. Haugen DR, Akslen LA, Varhaug JE, et al: Expression of c-erbB-2 protein in papillary thyroid carcinomas. Br J Cancer 65:832-837, 1992.
46. Kanamori A, Abe Y, Yajima Y, et al: Epidermal growth factor receptors in plasma membranes of normal and diseased human thyroid glands. J Clin Endocrinol Metab 68:899-903, 1989.
47. Akslen LA, Myking AO, Salvesen H, et al: Prognostic impact of EGF-receptor in papillary thyroid carcinoma. Br J Cancer 68:808-812, 1993.
48. Braga-Basaria M, Ringel MD: Clinical review 158: Beyond radioiodine: A review of potential new therapeutic approaches for thyroid cancer. J Clin Endocrinol Metab 88:1947-1960, 2003.
49. Goretzki PE, Simon D, Frilling A, et al: Surgical reintervention for differentiated thyroid cancer. Br J Surg 80:1009-1012, 1993.
50. Grunwald F, Menzel C, Bender H, et al: Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 39:1903-1906, 1998.
51. Van Herle AJ, Agatep ML, Padua DN, 3rd, et al: Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA R0 82 W-1) in vitro. J Clin Endocrinol Metab 71:755-763, 1990.
52. Schmutzler C, Winzer R, Meissner-Weigl J, et al: Retinoic acid increases sodium/ iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 240:832-838, 1997.
53. Elisei R, Vivaldi A, Agate L, et al: All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes. J Clin Endocrinol Metab 90:2403-2411, 2005.
54. Simon D, Koehrle J, Reiners C, et al: Redifferentiation therapy with retinoids: Therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 22:569-574, 1998.
55. Park JW, Duh QY, Clark OH: Potentially new therapties in thryoid cancer, in Clark OH, Duh QY, Kebebew E (eds): Textbook of Endocrine Surgery, 2nd ed, pp 334-343. Philadelphia, Elsevier Saunders, 2005.
56. Kebebew E, Wong MG, Siperstein AE, et al: Phenylacetate inhibits growth and vascular endothelial growth factor secretion in human thyroid carcinoma cells and modulates their differentiated function. J Clin Endocrinol Metab 84:2840-2847, 1999.
57. Eigelberger MS, Wong MG, Duh QY, et al: Phenylacetate enhances the antiproliferative effect of retinoic acid in follicular thyroid cancer. Surgery 130:931-935, 2001.
58. Ohta K, Endo T, Haraguchi K, et al: Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 86:2170-2177, 2001.
59. Park JW, Zarnegar R, Kanauchi H, et al: Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 15:222-231, 2005.
60. Martelli ML, Iuliano R, Le Pera I, et al: Inhibitory effects of peroxisome proliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab 87:4728-4735, 2002.
61. Shen WT, Chung WY: Treatment of thyroid cancer with histone deacetylase inhibitors and peroxisome proliferator-activated receptor-gamma agonists. Thyroid 15:594-599, 2005.
62. Zarnegar R, Brunaud L, Kanauchi H, et al: Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using trichostatin A, a histone deacetylase inhibitor. Surgery 132:984-990; discussion 990, 2002.
63. Kitazono M, Robey R, Zhan Z, et al: Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 86:3430-3435, 2001.
64. Zhong WB, Wang CY, Chang TC, et al: Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology 144:3852-3859, 2003.
65. Di Matola T, D'Ascoli F, Luongo C, et al: Lovastatin-induced apoptosis in thyroid cells: Involvement of cytochrome c and lamin B. Eur J Endocrinol 145:645-650, 2001.
66. Wang CY, Zhong WB, Chang TC, et al: Lovastatin, a 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 88:3021-3026, 2003.
67. Drosten M, Stiewe T, Putzer BM: Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model. Hum Gene Ther 14:971-982, 2003.
68. Iuliano R, Trapasso F, Le Pera I, et al: An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo. Cancer Res 63:882-886, 2003.
69. Chung HK, Yi YW, Jung NC, et al: Gadd45gamma expression is reduced in anaplastic thyroid cancer and its reexpression results in apoptosis. J Clin Endocrinol Metab 88:3913-3920, 2003.
70. Nagayama Y, Shigematsu K, Namba H, et al: Inhibition of angiogenesis and tumorigenesis, and induction of dormancy by p53 in a p53-null thyroid carcinoma cell line in vivo. Anticancer Res 20:2723-2728, 2000.
71. Kim SB, Ahn IM, Park HJ, et al: Growth inhibition and chemosensitivity of poorly differentiated human thyroid cancer cell line (NPA) transfected with p53 gene. Head Neck 23:223-229, 2001.
72. Nagayama Y, Yokoi H, Takeda K, et al: Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J Clin Endocrinol Metab 85:4081-4086, 2000.
73. Narimatsu M, Nagayama Y, Akino K, et al: Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line. J Clin Endocrinol Metab 83:3668-3672, 1998.
74. Nishihara E, Nagayama Y, Mawatari F, et al: Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo. Endocrinology 138:4577-4583, 1997.
75. Braiden V, Nagayama Y, Iitaka M, et al: Retrovirus-mediated suicide gene/prodrug therapy targeting thyroid carcinoma using a thyroid-specific promoter. Endocrinology 139:3996-3999, 1998.
76. Zhang R, Straus FH, DeGroot LJ: Adenoviral-mediated gene therapy for thyroid carcinoma using thymidine kinase controlled by thyroglobulin promoter demonstrates high specificity and low toxicity. Thyroid 11:115-123, 2001.
77. Smit JW, Shroder-van der Elst JP, Karperien M, et al: Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line. Thyroid 10:939-943, 2000.
78. Smit JW, Schroder-van der Elst JP, Karperien M, et al: Iodide kinetics and experimental (131)I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line. J Clin Endocrinol Metab 87:1247-1253, 2002.
79. Petrich T, Knapp WH, Potter E: Functional activity of human sodium/iodide symporter in tumor cell lines. Nuklearmedizin 42:15-18, 2003.
80. Zhang R, DeGroot LJ: An adenoviral vector expressing functional heterogeneous proteins herpes simplex viral thymidine kinase and human interleukin-2 has enhanced in vivo antitumor activity against medullary thyroid carcinoma. Endocr Relat Cancer 8:315-325, 2001.
81. Zhang R, DeGroot LJ: Genetic immunotherapy of established tumours with adenoviral vectors transducing murine interleukin-12 (mIL12) subunits in a rat medullary thyroid carcinoma model. Clin Endocrinol (Oxf) 52:687-694, 2000.
82. Zhang R, DeGroot LJ: Gene therapy of a rat follicular thyroid carcinoma model with adenoviral vectors transducing murine interleukin-12. Endocrinology 144:1393-1398, 2003.
83. Barzon L, Bonaguro R, Castagliuolo I, et al: Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and herpes simplex virus thymidine kinase. Eur J Endocrinol 148:73-80, 2003.